FG
PRME icon

Fairman Group’s Prime Medicine PRME Stock Holding History

Fairman Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84K Hold
500
– – ﹤0.01% 289
2026
Q1 		$1.74K Hold
500
– – ﹤0.01% 285
2025
Q4 		$1.74K Hold
500
– – ﹤0.01% 293
2025
Q3 		$2.77K Hold
500
– – ﹤0.01% 219
2025
Q2 		$1.24K Hold
500
– – ﹤0.01% 218
2025
Q1 		$1.46K Hold
500
– – ﹤0.01% 210
2024
Q4 		$1.46K Hold
500
– – ﹤0.01% 239
2024
Q3 		$1.94K Hold
500
– – ﹤0.01% 279
2024
Q2 		$2.57K Hold
500
– – ﹤0.01% 246
2024
Q1 		$3.5K Hold
500
– – ﹤0.01% 213
2023
Q4 		$4.43K Buy
+500
New +$3.85K ﹤0.01% 200

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fairman Group's PRME Position: Q2 2026 in Review

Fairman Group held its Prime Medicine (PRME) position steady in Q2 2026 at 500 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #289.

Fairman Group first reported a position in PRME in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.43K in Q4 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Fairman Group held 500 shares of Prime Medicine worth $1.84K as of Q2 2026.
  • Fairman Group left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Fairman Group's portfolio in Q2 2026, its #289 holding.
  • Fairman Group first reported a position in Prime Medicine in Q4 2023 and has held it in 11 quarters since.
  • Fairman Group's Prime Medicine position peaked at $4.43K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.